Anlotinib Hydrochloride for Soft Tissue Sarcoma Patients.
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Soft Tissue Sarcoma
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 70 years
- Gender
- Both males and females
Description
This regional multi-center study is planned to be carried out in Guangdong and Sichuan provinces. 48 cases are preliminarily expected to be included. The study will start in January 2019 and end in December 2019. It is expected that the trial will end in December 2020. This study evaluating the safe...
This regional multi-center study is planned to be carried out in Guangdong and Sichuan provinces. 48 cases are preliminarily expected to be included. The study will start in January 2019 and end in December 2019. It is expected that the trial will end in December 2020. This study evaluating the safety and efficacy of anlotinib as a maintenance treatment in advanced soft tissue sarcoma. All those participants need to sign informed consent forms for data collection and be used for research purpose before inclusion. Participants remained PR/SD after ?4 cycles of anthracyclines could be enrolled. 48 subjects with advanced soft tissue sarcoma will receive anlotinib at a dose of 12 mg once daily (day1-14 PO) in 21-day cycles until disease progression (defined by RECIST version 1.1) or unacceptable toxicity.
Tracking Information
- NCT #
- NCT03890068
- Collaborators
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Investigators
- Not Provided
Get Well Soon